Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019
Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval
SAN DIEGO , May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...
The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.
Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau
Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735
Viking Therapeutics stock faces near-term pressure, but its GLP-1 pipeline and clinical timeline could deliver significant long-term upside
Find out the major metrics that really matter when it comes to finding quality stocks, no matter how you prefer to play the market.
Conference call scheduled for 4:30 p.m. ET today
Barchart Research What to Expect from VKTX Earnings VKTX Generated April 28, 2026 Current Price $32.39 EPS Estimate $$-0.95 Consensus Rating Strong Buy Average Move 9.63% Viking Therapeutics Reports Another...